Skip to main content
SpringerLink
Log in

Metastasiertes Lungenkarzinom

Immunkombination schlägt Chemotherapie bei NSCLC mit hoher Mutationslast

  • journal club
  • Published:
InFo Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Hellmann MD et al. N Engl J Med 2018;378(22):2093–104

    Article  CAS  Google Scholar 

  2. Lawrence MS et al. Nature. 2013;499(7457):214–8

    Article  CAS  Google Scholar 

  3. Yarchoan M et al. N Engl J Med. 2017;377(25):2500–1

    Article  Google Scholar 

  4. Ramalingam SS et al. Cancer Res. 2018;78(13 Suppl):CT078

    Article  Google Scholar 

  5. Hellmann MD et al. Lancet Oncol. 2017;18(1):31–41

    Article  CAS  Google Scholar 

Literatur

  • Hellmann MD et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378 (22):2093–104

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin IV, Chemnitz, Deutschland

    Stefan Hammerschmidt

Authors
  1. Stefan Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Hammerschmidt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hammerschmidt, S. Immunkombination schlägt Chemotherapie bei NSCLC mit hoher Mutationslast. Info Onkol. 21, 16–17 (2018). https://doi.org/10.1007/s15004-018-6264-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-018-6264-4

Search

Navigation